GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness MELBOURNE, Australia, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies (GTG) is proud to provide details of a series of recent transformative initiatives. Our commitment to advancing early...

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health,...

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...

Cardinal Analytx and Premera Blue Cross partner to predict and mitigate customers’ high healthcare costs PALO ALTO, Calif., and MOUNTLAKE TERRACE, Wash., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Cardinal Analytx Solutions, a predictive healthcare analytics company, today announced an industry-leading...